Alkermes (ALKS) EBITDA (2010 - 2026)
Alkermes' EBITDA came in at $48.63 million for Q2 2026, down 51.8% from $100.8 million a year earlier.
Powered by 
Analysis
Alkermes (ALKS) EBITDA (2010 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Alkermes reported EBITDA of $178.89 million, down 55.6% year-over-year; for FY2025, it came in at $281.12 million, down 37.4% from FY2024.
- Going back by year, EBITDA was $449.17 million in FY2024 (-8.2%), $489.05 million in FY2023 (+581.4%), $71.77 million in FY2022 (-59.3%) and $176.4 million in FY2021.
- The five-year range for quarterly EBITDA is -$41.04 million (Q3 2022) to $300.28 million (Q2 2023).
- Year-over-year, EBITDA increased in two of the last seven quarters, with an average decline of 9.3%.
- The fastest year-over-year change in EBITDA over five years came in Q1 2024 (growth of 563.5%), and the weakest in Q4 2025 (a decline of 63.5%).
- Business Quant data shows ALKS's EBITDA at -$28.85 million (Q1 2026), $61.95 million (Q4 2025) and $97.16 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 9.10 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 8.33 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 999.00 Mn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 5.09 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 4.63 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -9.70 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 5.89 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 1.30 Bn |
| 10 | Alkermes | 6.73 Bn | 3.86 Bn | 397.90 Mn | 48.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.63 Mn |
| Mar 31, 2026 | -28.85 Mn |
| Dec 31, 2025 | 61.95 Mn |
| Sep 30, 2025 | 97.16 Mn |
| Jun 30, 2025 | 100.80 Mn |
| Mar 31, 2025 | 21.21 Mn |
| Dec 31, 2024 | 169.54 Mn |
| Sep 30, 2024 | 111.73 Mn |
| Jun 30, 2024 | 116.54 Mn |
| Mar 31, 2024 | 51.37 Mn |
| Dec 31, 2023 | 73.17 Mn |
| Sep 30, 2023 | 107.86 Mn |
| Jun 30, 2023 | 300.28 Mn |
| Mar 31, 2023 | 7.74 Mn |
| Dec 31, 2022 | 135.27 Mn |
| Sep 30, 2022 | -41.04 Mn |
| Jun 30, 2022 | -15.07 Mn |
| Mar 31, 2022 | -7.39 Mn |
| Dec 31, 2021 | 150.56 Mn |
| Sep 30, 2021 | -268,000.00 |
API Access
Alkermes EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=ALKS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "ALKS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=ALKS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();